Clinical Benefit of Delamanid (OPC-67683) in the Treatment of Multidrug-Resistant Tuberculosis Patients in China

Cell Biochemistry and Biophysics

Volumn 67, Issue 3, 2013, Pages 957-963

  Zhang, Qing ^a   Liu, Yidian ^a   Tang, Shenjie ^a   Sha, Wei ^a   Xiao, Heping ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Delamanid; MDR TB; Multidrug resistance; Tuberculosis

Indexed keywords

DELAMANID; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CHINA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INSOMNIA; MALE; MENTAL DISEASE; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; PHASE 2 CLINICAL TRIAL; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHINA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NITROIMIDAZOLES; OXAZOLES; PLACEBO EFFECT; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84888370233     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9589-5     Document Type: Article

References (24)

1. Wright, A., Zignol, M., van Deun, A., et al. (2009). Epidemiology of antituberculosis drug resistance 2002-07: An updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet, 373, 1861-1873.
2. Kim, D. H., Kim, H. J., Park, S.-K., et al. (2008). Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine, 178, 1075-1082.
3. Kwon, Y. S., Kim, Y. H., Suh, G. Y., et al. (2008). Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clinical Infectious Diseases, 47, 496-502.
4. Mitnick, C., Castro, K., Harrington, M., Sacks, L., & Burman, W. (2007). Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Medicine, 4, e292.
5. World Health Organization. (2008). Global tuberculosis control: Surveillance, planning, financing. WHO report 2008. WHO/HTM/TB/2008. 393. Geneva, Switzerland.
6. World Health Organization. (2010). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010. 3.
7. Stop TB Partnership and World Health Organization. (2006). Global plan to stop TB 2006-2015. WHO/HTM/STB/2006. 35 Geneva: World Health Organization.
8. World Health Organization. (2006). Addressing the threat of tuberculosis caused by extensively drug-resistant Mycobacterium tuberculosis. Weekly Epidemiology Record, 81, 386-390.
9. Matsumoto, M., Hiroyuki, H., Tatsuo, T., et al. (2006). OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. Public Library Science Medicine, 3, e466.
10. Matsumoto M. (2003). In vitro activities of OPC-67683 and reference compounds against Mycobacterium tuberculosis standard strains and Mycobacterium bovis strains. Otsuka Study No. 019064.
11. Matsumoto M. (2003). In vitro activities of OPC-67683 and reference compounds against clinically isolated Mycobacterium tuberculosis. Otsuka Study No. 019196, Otsuka Report No. 019196, Otsuka Report No. 015366.
12. Matsumoto M. (2005). Inhibitory activity of OPC-67683 against mycolic acid synthesis in Mycobacterium bovis BCG. Otsuka Study No. 021327, Otsuka Report No. 017300.
13. Gler, M. T., Skripconoka, V., Sanchez-Garavito, E., et al. (2012). Delamanid for patients with multi-drug resistant pulmonary tuberculosis. The New England Journal of Medicine, 366, 1-10.
14. World Health Organization (2008). Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update 2008. WHO/HTM/TB/2008. 402.
15. World Health Organization. (2010). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010. 3.
16. Schecter, G. F., Scott, C., True, L., Raftery, A., Flood, J., & Mase, S. (2010). Linezolid in the treatment of multidrug-resistant tuberculosis. Clinical Infectious Diseases, 50, 49-55.
17. Chan, E., & Iseman, M. (2008). Multidrug-resistant and extensively drug-resistant tuberculosis: A review. Current Opinion in Infectious Diseases, 21, 587-595.
18. Orenstein, E. W., Basu, S., Shah, N. S., et al. (2009). Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infectious Diseases, 9, 153-161.
19. Johnston, J. C., Shahidi, N. C., Sadatsafavi, M., et al. (2009). Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS ONE, 4(9), e6914.
20. Mitnick, C., Bayona, J., Palacios, E., et al. (2003). Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. The New England Journal of Medicine, 348, 119-128.
21. Leimane, V., Reikstina, V., Holtz, T., et al. (2005). Clinical outcomes of individualized treatment of multidrug-resistant tuberculosis in Latvia: A retrospective cohort study. Lancet, 365, 318-326.
22. Caminaro, J. A. (2006). Treatment of multidrug-resistant tuberculosis: Evidence and controversies. International Journal of Tuberculosis and Lung Diseases, 10, 829-837.
23. Chan, E. D., Laurel, V., Strand, M. J., et al. (2004). Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. American Journal of Critical Care Medicine, 169, 1103-1109.
24. WHO. (2006). Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO.